Related Experiment Video

Updated: Jun 27, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development

Yoshihiro Oka1, Akihiro Tsuboi, Fumihiro Fujiki

  • 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2, Yamada-Oka, Suita City, Osaka 565-0871, Japan. yoshi@imed3.med.osaka-u.ac.jp

Current Medicinal Chemistry
|December 17, 2008
PubMed

Insights

Cancer immunotherapy using Wilms' tumor gene WT1 peptide vaccines shows promise. Clinical trials report positive responses in various cancers, with potential for pediatric malignancies and enhanced therapies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Cancer immunotherapy is advancing, with tumor-associated antigens as key targets.
  • Wilms' tumor gene WT1 protein is a promising antigen due to its oncogenic function and expression in malignancies.
  • WT1 protein has demonstrated significant immunogenicity in cancer patients.

Purpose of the Study:

  • To identify and develop WT1 peptide vaccines for cancer immunotherapy.
  • To evaluate the efficacy of WT1 peptide vaccination in patients with specific HLA types.
  • To explore strategies for enhancing the effectiveness of WT1 peptide vaccines.

Main Methods:

  • Identification of WT1 cytotoxic T lymphocyte (CTL) epitopes restricted by HLA-A 0201 and HLA-A 2402.
  • Clinical trials involving WT1 peptide vaccination in cancer patients.
  • Analysis of immunological and clinical responses post-vaccination.

Main Results:

  • WT1 CTL epitopes restricted by HLA-A 0201 and HLA-A 2402 were identified.
  • Clinical trials demonstrated immunological and/or clinical responses in patients with myeloid malignancies, multiple myeloma, and solid cancers.
  • Pediatric malignancies are potential future targets for WT1 peptide vaccination.

Conclusions:

  • WT1 peptide vaccination is a viable immunotherapy strategy for various cancers.
  • Enhancements such as adding HLA class II-restricted helper epitopes or combining with chemotherapy may improve vaccine efficacy.
  • Future developments include gene therapy and DNA vaccination targeting WT1.

More Related Videos

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.